A retrospective clinical trial showed that treatment with tocilizumab, a monoclonal antibody against IL-6R, reduced oxygen requirements, serum level of CRP, and hospital stays, as well as improving lymphocyte recovery and clinical outcomes in severe or critical COVID-19 (217). The gene discussed is IL6R; the disease is COVID-19.